GlassScriptPhysician profile
Donald M Rusthoven
NPI 1861460727
$14,041.66
in general payments reported to CMS, 2019-2025
49 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,591 · 2020: $1,016 · 2021: $2,270 · 2022: $2,060 · 2023: $2,214 · 2024: $2,193 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,104.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,853.27 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,729.98 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,585.83 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $1,211.15 | 2019-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $1,059.57 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $980.79 | 2019-2025 | Evenity, Prolia |
| Amarin Pharma, INC. | $977.47 | 2019-2021 | |
| Pfizer INC. | $543.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $304.24 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Horizon Therapeutics Plc | $296.11 | 2022-2023 | Krystexxa |
| Madrigal Pharmaceuticals | $280.68 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $243.02 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $206.12 | 2021-2023 | |
| Lilly USA, LLC | $205.81 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Collegium Pharmaceutical, INC. | $187.60 | 2025 | Jornay Pm |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Rusthoven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.